Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

A Young Man with Non-alcoholic Steatohepatitis and Serum Anti-mitochondrial Antibody Positivity: A Case Report.

Seike T, Komura T, Shimizu Y, Omura H, Kumai T, Kagaya T, Ohta H, Kawashima A, Harada K, Kaneko S, Unoura M.

Intern Med. 2018 Jun 6. doi: 10.2169/internalmedicine.0405-17. [Epub ahead of print]

2.

[Non-alcoholic fatty liver disease and steatohepatitis].

Pár G, Horváth G, Pár A.

Orv Hetil. 2013 Jul 21;154(29):1124-34. doi: 10.1556/OH.2013.29626. Review. Hungarian.

PMID:
23853345
3.

Ursodeoxycholic acid for nonalcoholic steatohepatitis.

Wu SD, Li L, Wang JY.

Eur J Gastroenterol Hepatol. 2012 Nov;24(11):1247-53. Review.

PMID:
22864259
4.

High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.

Lindström L, Boberg KM, Wikman O, Friis-Liby I, Hultcrantz R, Prytz H, Sandberg-Gertzén H, Sangfelt P, Rydning A, Folvik G, Gangsøy-Kristiansen M, Danielsson A, Bergquist A.

Aliment Pharmacol Ther. 2012 Feb;35(4):451-7. doi: 10.1111/j.1365-2036.2011.04966.x. Epub 2012 Jan 5.

5.

The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study.

Martin CR, Blanco PG, Keach JC, Petz JL, Zaman MM, Bhaskar KR, Cluette-Brown JE, Gautam S, Sheth S, Afdhal NH, Lindor KD, Freedman SD.

Aliment Pharmacol Ther. 2012 Jan;35(2):255-65. doi: 10.1111/j.1365-2036.2011.04926.x. Epub 2011 Nov 30.

6.

High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.

Imam MH, Sinakos E, Gossard AA, Kowdley KV, Luketic VA, Edwyn Harrison M, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, DeCook AC, Enders F, Lindor KD.

Aliment Pharmacol Ther. 2011 Nov;34(10):1185-92. doi: 10.1111/j.1365-2036.2011.04863.x. Epub 2011 Sep 29.

7.

Primary sclerosing cholangitis: High-dose ursodeoxycholic acid is associated with risk of colonic neoplasia in patients with PSC and ulcerative colitis.

Franks I.

Nat Rev Gastroenterol Hepatol. 2011 Jul 4;8(7):361. doi: 10.1038/nrgastro.2011.99. No abstract available.

PMID:
21725347
8.

Primary sclerosing cholangitis and pregnancy.

Kammeijer CQ, De Man RA, De Groot CJ.

Clin Pract. 2011 Jul 1;1(3):e55. doi: 10.4081/cp.2011.e55. eCollection 2011 Jul 1.

9.

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.

Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Lindor KD.

Am J Gastroenterol. 2011 Sep;106(9):1638-45. doi: 10.1038/ajg.2011.156. Epub 2011 May 10.

10.

A case of recovery from canine destructive cholangitis in a Miniature Dachshund.

Osumi T, Ohno K, Kanemoto H, Nakashima K, Uchida K, Karasawa A, Fujino Y, Tsujimoto H.

J Vet Med Sci. 2011 Jul;73(7):937-9. Epub 2011 Feb 14.

11.

A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis.

Adams LA, Angulo P, Petz J, Keach J, Lindor KD.

Hepatol Int. 2010 Jul 28;4(3):628-33. doi: 10.1007/s12072-010-9195-1.

12.

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial.

Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, Zeuzem S, Hein J, Berg T; NASH Study Group.

Hepatology. 2010 Aug;52(2):472-9. doi: 10.1002/hep.23727.

PMID:
20683947
13.

Treatment options for primary sclerosing cholangitis.

Sinakos E, Lindor K.

Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):473-88. doi: 10.1586/egh.10.33. Review.

PMID:
20678020
14.

Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.

Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K.

Hepatology. 2010 Jul;52(1):197-203. doi: 10.1002/hep.23631.

15.

The predictors of the presence of varices in patients with primary sclerosing cholangitis.

Treeprasertsuk S, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Schmoll J, Hoskin T, Thapa P, Enders F, Lindor KD.

Hepatology. 2010 Apr;51(4):1302-10. doi: 10.1002/hep.23432.

16.

High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?

Chapman RW.

Hepatology. 2009 Sep;50(3):671-3. doi: 10.1002/hep.23174. No abstract available.

PMID:
19714717
17.

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.

Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F.

Hepatology. 2009 Sep;50(3):808-14. doi: 10.1002/hep.23082.

18.

Current diagnosis and management of primary sclerosing cholangitis.

Tischendorf JJ, Geier A, Trautwein C.

Liver Transpl. 2008 Jun;14(6):735-46. doi: 10.1002/lt.21456. Review.

19.

High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.

Silveira MG, Lindor KD.

J Hepatol. 2008 May;48(5):692-4. doi: 10.1016/j.jhep.2008.02.002. Epub 2008 Feb 14. No abstract available.

20.

High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.

Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW.

J Hepatol. 2008 May;48(5):792-800. doi: 10.1016/j.jhep.2007.12.023. Epub 2008 Feb 14.

PMID:
18314215

Supplemental Content

Loading ...
Support Center